Episode Description 

Leading through a period of trial

The biotechnology company Amgen produces two drugs for anemia that have earned the company billions of dollars. But new findings could result in strong warnings being placed on the drugs. Amgen CEO Kevin Sharer talked about his company's situation with Kai Ryssdal.
Posted In: Health

Watch out for those library fines

With Wall Street still caught up in its liquidity crisis, it's probably a good time for those with squeaky clean credit records to keep them that way. Commentator Susan Lee says you'd be surprised how much even the littlest things can hurt.
Posted In: Savings

Syria transfers to modern banking

Imagine a place with no loans, no checks and no credit cards. That was the Syrian economy just a couple of years ago. But now the government is modernizing the financial system, with private banks leading the way. Jennifer Glasse reports.
Posted In: Savings

KKR makes offer to reassure its lenders

The private-equity firm Kohlberg Kravis Roberts has agreed to conditions on loans it's taking out to buy the credit card processing firm First Data. Bob Moon explains.
Posted In: Investing, Wall Street

Troop cuts could mean contractor surge

General David Petraeus told Congress today that he believes the United States can reduce its presence in Iraq to pre-surge levels by next summer. Steve Henn reports that American defense contractors see that as a business opportunity.

An easy-to-read label is hard to find

FDA officials are debating whether changes in food labels might help consumers make healthy choices. Helen Palmer reports there are plenty of ideas but not much consensus.
Posted In: Health, Retail

Toy industry tries to get the lead out

U.S. and Chinese regulators are expected to adopt new standards to prevent products containing lead paint from entering the United States. But, as Amy Scott reports, with the holiday shopping season approaching, the toy industry is taking matters into its own hands.
Posted In: Retail